Piper Calls Valeant Management 'Overly Rosy,' Cuts Price Target To $10
March 01, 2018 at 09:45 AM EST
Management of Valeant Pharmaceuticals is taking an "overly rosy" long-term view of the business, Piper Jaffray analyst David Amsellem tells investors in a research note following the company's Q4 results.